Podcasts about clinical development

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

In this episode of the AGD Podcast Series, host George Schmidt, DMD, FAGD, speaks with Charles D. Schlesinger, DDS, FICOI, VP of Clinical Development at Impladent LTD, about the critical role of bone grafting in successful dental implant therapy. Dr. Schlesinger explains why grafting is often necessary to create an ideal foundation for implant placement, reviews the advantages and limitations of various grafting materials, and shares practical insights on treatment planning, healing timelines, and radiographic evaluation. The conversation also explores the science behind alloplastic grafting materials, including OsteoGen® crystals, and discusses applications such as socket preservation, sinus augmentation, and immediate implant placement. Drawing on decades of clinical and educational experience, Dr. Schlesinger offers valuable guidance for clinicians seeking to improve implant outcomes while highlighting emerging innovations and future directions in regenerative dentistry. Dr. Schlesinger graduated with honors from The Ohio State College of Dentistry and completed a General Practice Residency at the Veterans Affairs Medical Center in San Diego, later serving as Chief Resident at the Veterans Affairs Medical Center in West Los Angeles, where he received extensive training in oral surgery, implantology, and advanced restorative care.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at Boehringer Ingelheim. The conversation explores the crisis beyond obesity that many clinicians and health systems are now grappling with: that obesity can't be treated as a short-term, weight-loss lifestyle issue. Rather, it needs to be managed as a complex, chronic, multi-organ disease. Younes discusses how liver disease is often missed in cardiometabolic risk and is referred to as the ‘liver blind spot', as well as what integrated pathways can do to improve outcomes and ease system pressure.

OKYO Pharma's CEO Robert Dempsey joined Steve Darling from Proactive to announce the appointment of Dr. Marta Sacchetti, MD, PhD, as the newest member of the company's Scientific Advisory Board (SAB), a move designed to further strengthen the company's scientific and clinical expertise as it advances its lead ophthalmic programs. Dempsey explained that Sacchetti's addition enhances OKYO Pharma's already distinguished global network of scientific and medical advisors. Widely recognized for her expertise in neuro-inflammatory corneal diseases, Sacchetti brings deep knowledge and extensive research experience that aligns with the company's mission to address significant unmet needs in ophthalmology and ocular surface disease treatment. Sacchetti currently serves as an Associate Professor of Ophthalmology at Link University in Rome, Italy, and has built a strong reputation through her work spanning clinical practice, research, and industry collaboration. Her previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici adds another important dimension to her expertise, particularly in areas involving targeted nerve regeneration, pain signaling modulation, and advanced diagnostic approaches. Her research efforts have focused heavily on degenerative, allergic, and neuroimmune diseases affecting the cornea and ocular surface. In addition to her clinical contributions, Sacchetti has authored numerous peer-reviewed scientific publications and presented her findings at leading national and international conferences, reinforcing her standing within the global ophthalmology community. Dempsey noted that her appointment comes at an important stage for OKYO Pharma as the company advances its investigational treatment pipeline. The company's lead product candidate, Urcosimod, continues to gain attention as the first investigational therapy to receive an Investigational New Drug (IND) designation specifically for the treatment of neuropathic corneal pain. The program has also been granted Fast Track designation by the U.S. Food and Drug Administration, potentially accelerating its path through development and regulatory review. The appointment reflects OKYO Pharma's ongoing strategy of adding specialized expertise to support the development and commercialization of novel therapies aimed at addressing challenging ophthalmic conditions. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #HealthcareInnovation #ClinicalDevelopment #NeuroInflammation #CornealDisease #Pharmaceuticals #MedTech #DrugDevelopment #MartaSacchetti

Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1, FBXW7, and PPP2R1A-altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50% at the potential recommended phase 2 dose. These data were presented by Timothy A. Yap, MBBS, PhD, FRCP, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following his presentation, Yap joined CancerNetwork® for a discussion where he highlighted some of the most interesting takeaways from the trial. According to Yap, the disease states evaluated in this trial represent areas of unmet need where no specific standard-of-care options can target these alterations.Notably, based on results from this trial, the FDA granted fast track designation to lunresertib in combination with zedoresertib in patients with genomic-defined platinum-resistant ovarian cancer.2Yap is a medical oncologist and physician-scientist, as well as the Random Horne, Jr. Endowed Professor for Cancer Research and vice president and head of Clinical Development in the Therapeutics Discovery Division at UT MD Anderson Cancer Center.References1.        Yap TA, Aggarwal R, Fontana E, et al. First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. Presented at the 2026 AACR Annual Meeting; April 17-22, 2026; San Diego, CA. Abstract CT022.2.        Following oral presentation of phase I Data at AACR 2026, Debiopharm announces FDA fast track designation for lunresertib in combination with zedoresertib for genomic-defined platinum-resistant ovarian cancer. News release. Debiopharm. April 20, 2026. Accessed May 4, 2026. https://shorturl.at/n1bWn

Episode Overview In this episode, I speak with Anna Mosikian, a physician by training and Global Clinical Program Lead working at the intersection of clinical development and strategic marketing. Anna brings a powerful perspective on how clinical data translates into real-world value—bridging evidence generation, regulatory expectations, and commercial impact. We dive into what clinical leaders truly expect from statisticians and how statisticians can move from technical contributors to strategic partners. We explore what “good collaboration” really looks like in practice, why understanding the purpose of a study is critical, and how statisticians can elevate their impact through communication, proactiveness, and cross-functional thinking.

What if the most dangerous part of brain tumor treatment isn't the surgery… but the wait that comes after it? In this episode of Med Tech Gurus, we sit down with Dr. Michael Garcia, Chief Medical Officer and Head of Clinical Development at GT Medical Technologies, and one of the leading voices reshaping how we treat brain tumors. Dr. Garcia leads the clinical strategy behind GammaTile® — an implantable, bioabsorbable device that delivers targeted radiation from inside the brain immediately after surgery, eliminating the dangerous 3–6 week delay where tumors often begin to grow back. Under his leadership, GT Medical has reported powerful interim clinical data showing GammaTile can reduce the risk of recurrence or death by more than 50% compared to standard of care — with no increase in safety concerns. Today, more than 150 leading cancer centers are using this technology, changing not only outcomes, but something equally important: patient experience. Less anxiety. Fewer treatment delays. Fewer logistical burdens. More hope. Dr. Garcia shares the science, the strategy, and the deeply personal mission behind this innovation — along with insights on clinical trial design, multidisciplinary collaboration, and building medtech that truly serves patients. If you care about oncology, neurosurgery, innovation with purpose, or patient-centered design, this is a conversation you won't want to miss.

Not all capital is created equal. After 10 years building a med spa from the ground up, the offers started coming in. One looked perfect — until it wasn't. In this episode of Medical Spa Insider, host Alex Thiersch interviews Maegen Kennedy, MMS, PA-C, Founder of Windermere Medical Spa and Head of Clinical Development at AYA Skin. This is the unfiltered story of walking away from a private equity deal, spending two years getting crystal clear on what a real growth partnership looks like, and finally finding a company built to scale a legacy — not just extract one. If you're a med spa owner thinking about your next chapter, this conversation will change how you approach it. The discussion includes: How to Approach Business Growth with Strategy and Intentionality The Importance of Staying Customer-Focused while Scaling Why the First Deal Might Not Be the Best Deal Recognizing and Preserving Core Values while Pursuing a Partnership Trusting Your Instincts while Finding Your Right Fit  

In Part 3, Hideki Garren, Roche, shares a hopeful vision for slowing, stopping and ultimately preventing multiple sclerosis. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.

In Part 2, Hideki Garren, Roche, discusses the challenge of measuring MS progression and the importance of better data, imaging and patient insight. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.

This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients. In Part 1, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Mackinnon, senior vice president and executive general manager at Medable, about leveraging AI to transform clinical development and accelerate lifesaving therapies to patients. Mackinnon discusses ‘white space' in R&D, about integrating generative and agentic AI with human-in-the-loop oversight while prioritising patient safety and regulatory, and how all this advances health equity for underserved communities. You can listen to episode 248 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Synopsis: Fresh from the JPM 2026 in San Francisco, Alok Tayi welcomes Johan Luthman, Executive Vice President of R&D at Lundbeck, for a sweeping, deeply personal conversation on the future of neuroscience drug development. From his early days as a Swedish clinician-scientist to leading breakthrough Alzheimer's programs and rebuilding Lundbeck's pipeline from the ground up, Johan shares the pivotal moments—and phone calls—that shaped a 30-year career across AstraZeneca, Merck, Serono, and now Denmark's neuroscience powerhouse. The discussion dives into Lundbeck's bold strategic reset: letting biology lead, de-risking early in patients, embracing rare disease and sleep medicine, and making disciplined bets on monoclonal antibodies, migraine prevention, epilepsy, and neuroendocrine disorders. Johan explains how the company shifted capital toward innovation, rebuilt its portfolio through targeted acquisitions, and built one of the most advanced neuroscience pipelines in pharma today. In one of the episode's most powerful moments, Johan opens up about his personal motivation—caring for family members with Alzheimer's and dedicating his career to diseases of the brain. From AI-driven R&D productivity and adaptive trials to Denmark's unique foundation-owned pharma model, this conversation is a masterclass in scientific rigor, decision-making under uncertainty, and keeping patients at the center of everything. Biography: In 1991, Johan Luthman began his career in the pharmaceutical industry in Astra, later AstraZeneca. In 2005, Johan joined Serono as Head of Neuroscience & Immunology Research, and subsequently, in MerckSerono, as Therapy Area Head, Neurology & Immunology. In 2009, he became CEO of biotech start-up GeNeuro. In late 2009, Johan joined Merck as VP & Franchise Integrator for Neuroscience and Ophthalmology. In 2014, he came to Eisai where he was Senior Vice President and Head of Clinical Development. Johan joined Lundbeck as Executive Vice President, R&D in March 2019. Johan is a Swedish national and is trained as a Doctor of Dental Sciences from the Karolinska Institute, Sweden. He also holds a PhD in Neurobiology and Histology as well as an Associate Professor title from the Karolinska Institute, Sweden. Johan is a Member of the Board of Directors of Brain+.

For years, patient involvement in drug development was limited to trial participation and post-approval education. But things are evolving. Patients today aren't just participants—they actively co-build the healthcare ecosystem.In today's podcast episode, experts from the MAPS Scientific & Technical Knowledge Domain dive into a topic that's transforming clinical development: Patient engagement.

Generative AI is moving fast—and in pharma, it's no longer just a buzzword. In this episode of The Effective Statistician Podcast, I speak with Manuel Cossio about how Generative AI is already being applied in real-world pharma settings, where it's delivering value today, and what still needs careful consideration in regulated environments. Manuel brings a unique hybrid background, combining molecular biology, genetics, pharma experience, and deep AI engineering expertise. He works at the cutting edge of AI in clinical development, including agentic systems, human-in-the-loop approaches, and large-scale document automation. This conversation goes well beyond theory. We focus on practical use cases, real limitations, and how statisticians, programmers, and data scientists can responsibly use GenAI to become more effective.

Friday, January 16, 2026 - Week 3   Stoke Phase 3 Rapid Recruitment - A timeline that is ours to beat! https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-updates-timelines-completion   If Marcin can make it from Poland, you can make it from where you are! cureSYNGAP1.org/Marcin   CAMP4 Website is great and features Dani Williams! https://www.camp4tx.com/   Newsletter is out! https://cureSYNGAP1.org/NL49    Sara Driscoll Genetic Testing Story - Share it or copy it! https://cureSYNGAP1.org/GenTest   Pubmed 2026 is at 3! https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date   SOCIAL MATTERS 4,604 LinkedIn.  https://www.linkedin.com/company/curesyngap1/ 1,510 YouTube.  https://www.youtube.com/@CureSYNGAP1 11.2k Twitter https://twitter.com/cureSYNGAP1 45k Insta https://www.instagram.com/curesyngap1/   $CAMP stock is at $5.78 on 15 Jan. ‘26 https://www.google.com/finance/beta/quote/CAMP:NASDAQ   Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10/ Episode 196 of #Syngap10 #CureSYNGAP1 #Podcast

In this episode of the World Extreme Medicine Podcast, host Eoin Walker speaks with Simon Robinson, former Royal Marine Commando Paramedic turned Head of Clinical Development in Urgent Care.Together, they explore the evolving role of paramedics in primary care, from emergency response to diagnosis, prescribing, and leading multidisciplinary teams. Simon shares insights on:The transition from frontline emergency work to primary careIndependent prescribing and clinical autonomyTraining, mentorship, and building multidisciplinary teamsThe challenges and opportunities paramedics face outside traditional ambulance rolesWhether you're a student paramedic, an experienced clinician, or simply curious about the future of urgent care—this conversation offers an honest, practical look at how the profession is growing beyond its emergency roots.Find out more about the College of Paramedics.

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.

Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.

Widex has expanded its Allure™ hearing aid platform with new form factors and charging options, giving hearing care professionals more flexibility across a wider range of patient needs. In this discussion, Dana Helmink, Au.D., Senior Director of Clinical Development at WSA, walks through the addition of a rechargeable Allure BTE, Widex's first rechargeable ITE, and a new portable charger for the Allure RIC — designed to support travel, active lifestyles, and extended daily use.The conversation also explores updates to Widex Compass Cloud™, the company's cloud-based fitting software. Dana explains how frequent rolling updates, precision fitting tools, and in-ear measurement capabilities like the Allure Sensogram are designed to improve first-fit accuracy, reduce follow-up visits, and support more personalized fittings. The shift to cloud-based software allows Widex to release new features on an accelerated schedule without requiring manual software installs.Together, the platform updates reflect Widex's continued focus on natural sound, speech clarity, and environmental awareness. The discussion also touches on the role of the W1 chip, backwards-compatible firmware upgrades, AI-supported personalization through the Widex app, and how these advances translate into real-world patient outcomes in complex listening environments.For more information on the Allure portfolio expansion: https://hearinghealthmatters.org/hearing-technologies/2025/widex-expands-allure-portfolio-with-new-hearing-aid-models-and-charger/Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.- https://x.com/WeekinHearing- https://www.instagram.com/thisweekinhearing/- https://www.linkedin.com/company/this-week-in-hearingVisit us at: https://hearinghealthmatters.org/thisweek/

Join host David Wild as he speaks with Stacie Bell, chief clinical research officer at Lupus Therapeutics, about the dramatic transformation happening in lupus drug development. From a field once avoided by pharma companies to one generating unprecedented excitement, Bell discusses how her organization's 62-center network is revolutionizing clinical trials through patient engagement and scientific innovation. Learn about promising oral therapies, Genentech's cancer drug Gazyva under FDA review for lupus nephritis, cell therapy approaches offering potential long-term remission and how combination treatments may become the new standard. Bell shares insights on overcoming clinical trial barriers, advancing biomarker research and ensuring representative participation from lupus communities. A must-listen for anyone interested in autoimmune disease research, clinical development innovation, and patient-centered drug development.

“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.”  This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Join Dr. Mohamed Abou-el-Enein, Editor-in-Chief of Molecular Therapy Methods & Clinical Development, as he discusses a recent article published in MTMCD with co-authors Drs. Daniel Stone, Harrison Dulin, and Keith R. Jerome from the Fred Hutchinson Cancer Center. The article, “Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice,” will appear in MTMCD’s upcoming special issue, Lipid nanoparticles for cell and gene therapy. If you enjoy this episode, check out our hybrid event this fall that will allow you to engage with pioneering researchers in gene editing! Breakthroughs in Targeted In Vivo Gene Editing will be held in San Diego and virtually November 20-21. Register to secure your spot or submit an abstract through Sept. 12 for the opportunity to present your research! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

On this exciting episode of the IPhO Podcast, we're shining a spotlight on the unique experiences of fellows working in one of the most critical phases of drug development: late-stage clinical development! Joining us are three fellows from the Merck Late Stage Clinical Development Fellowship Program: Vivian Tran, PharmD, Late Stage Clinical Development, General and Specialty Medicine; Lauren Dougherty, PharmD, Late Stage Clinical Development, Oncology; and Shakhzoda Rakhimova, PharmD, RPh, Late Stage Clinical Development, ID/Vaccines. In this conversation with their co-fellow and host, Alena Abraham, PharmD, they share their personal journeys into clinical development, what guided them toward their specific therapeutic areas, and how they've tackled common challenges, such as steep learning curves and navigating collaboration difficulties. They also highlight the key skills that have helped them thrive in their roles and offer valuable advice for students considering a similar path. Whether you're exploring fellowship options or have a strong interest in clinical development, this episode offers insider insight you won't want to miss!

Courtney is back with Dr. Alisar Zahr, Senior Director of Research and Clinical Development at Revision Skincare, for part two of their conversation. In this episode, Alisar offers a deep dive into the product development process at Revision—how ideas become cutting-edge skincare formulations, and what it takes to bring a new product to life. She also shares some of her favorite treatments, the innovations she's most excited about, and a behind-the-scenes look at what's coming next from the lab. It's a must-listen for anyone curious about how science shapes the skincare products we trust.

*This podcast episode was originally a YouTube LIVE with Q&A which you can watch on my YouTube channel here. This is a series of episodes I am doing on non-traditional careers running from July to December 2025. Sign up to my shared Google Calendar here so you never miss an episode*In this episode of Pharmacist Diaries, I'm joined by Adam Quicaro, a pharmacist who transitioned into the world of clinical development at Alexion Pharmaceuticals, the rare disease arm of AstraZeneca. This conversation kicks off our brand-new series exploring non-traditional pharmacy careers — and Adam's story is the perfect place to start.Adam walks us through his journey from working in an independent community pharmacy during high school to landing a fellowship in medical affairs, and eventually finding his true calling in clinical development. He shares how his childhood curiosity and love for science led him to pharmacy, but how it was a blend of strategic thinking, innovation, and a desire to solve complex problems that pulled him toward the pharmaceutical industry.We explore the differences between medical affairs and clinical development, what a typical day looks like in his role, and why pharmacists are uniquely positioned to succeed in the pharma space — especially those with a strong foundation in therapeutics, pharmacology, and patient care.Adam also opens up about the realities of salary expectations, comparing entry-level roles and fellowships, and highlighting the long-term rewards of working in industry. He talks about the benefits of hybrid working, generous leave policies, and how this role supports him not just as a pharmacist, but as a new dad seeking balance and fulfillment.If you've ever wondered what it's like to work behind the scenes of a clinical trial, or if you're curious about how to pivot out of a traditional role, this episode is full of honest, practical advice and inspiration. Whether you're a student or seasoned pharmacist, Adam's story will get you thinking about what's possible.JOIN MY NEWSLETTER COMMUNITY:This isn't your typical pharmacy newsletter - it's a weekly mentoring session delivered straight to your inbox, packed with actionable insights for ambitious pharmacy students. Each week, I share:Building multiple income streams while maintaining clinical practiceTime management secrets and productivity hacks I swear by ⚡Systems and strategies that keep it all running smoothly ⚙️Personal reflections on growth, failure, and resilienceBehind-the-scenes looks at podcast production and brand buildingIf you are ready to think differently about your future in pharmacy, sign up

Courtney sits down with Dr. Alisar Zahr, Senior Director of Research and Clinical Development at Revision Skincare, to talk some hard science in her return to the Beauty Formula. In this episode, Courtney and Alisar discuss Alisar's unique educational background that has made her the type of Senior Director who you will find working in the lab instead of behind a desk. Alisar compares her experiences of running skincare product trials in Japan to her experiences doing the same in the United States. And finally, she provides a sneak peak at the newest skincare innovations that Revision is perfecting in the lab before they hit the market.

Synopsis: When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future. They dive into the evolution of REGENXBIO's pipeline, tackling ultra-rare diseases like MPS II, ambitious plans for Duchenne Muscular Dystrophy, and commercial partnerships with giants like AbbVie. Curran offers hard-earned leadership lessons, honest reflections on scaling science, and insights into how one-time gene therapies could revolutionize treatment in both rare and common diseases. From clinical nuance to strategic boldness, this is a masterclass in biotech leadership, platform focus, and staying patient-first—no matter how complex the science or market. Biography: Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company's Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company's Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.

As far as healthcare conferences go, the American Society of Clinical Oncology (ASCO) annual meeting is the top of the crop.Every year, thousands descend on Chicago for days worth of oncology-focused presentations, data readouts and industry-shaping news. Ahead of ASCO this weekend, Eisai's Dr. Corina Dutcus speaks with Pharma Editor Lecia Bushak to preview the annual oncology megaconference.Additionally, we dive into some data from the upcoming 2025 MM+M Agency 100 list, namely the representation of women at the C-suite level of leading medical marketing agencies. Also, don't forget to register to attend the 2025 Women of Distinction event on June 3 in New York. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Malaikannan Sankarasubbu (Chief Technology & AI Officer, Saama) and Jonathan Shough (Chief Information Officer, Parexel) join this week's episode to discuss how the strategic use of AI technologies is transforming clinical development. They dive deeper into which advancements in generative AI have the potential to improve the clinical trial workflow, the integration of AI and predictive analytics in risk assessment processes, and the importance of strong change management strategies when implementing new AI technologies.

May 20, 2025 ~ A new FDA-approved blood test, the Shield test, is available for colon cancer screening for people 45 and older. Guardian VP of Clinical Development, Dr. Sam Asgarian, talks with Lloyd, Jamie, and Chris about this alternative test to traditional methods and simplifying the screening process.

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics: Introduction (0:00) Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42) Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25) CME information and select publications

This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results.  One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. The interview starts with Yukti sharing information on her own academic and commercial background and how she came to this role. She describes FibroSIGHT, a service that will provide a highly accurate CRN fibrosis level for patients whose NIT results suggest no clear or consistent finding. Yukti provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit in this analysis. Roger goes on to express concern that any option requiring more biopsies will reduce the number of patients treated, particularly if having this tool encourages payers to require a biopsy as a prerequisite to treatment. He asks whether, over time, HistoIndex might be able to develop a companion analytic to improve these estimates without requiring biopsy. 

00:00:00 - Surf's Up: Season 6 Episode 3Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical trial questions. Our newsmaker, HistoIndex Director of Clinical Development Yukti Choudhury, introduces us to FibroSIGHT, which provides clinicians with highly precise biopsy analysis. Finally, our expert, Global Liver Institute Vice President, Liver Programs Jeff McIntyre, discusses the implications of recent US government job cuts on future MASH treatment options and patient care.00:04:35 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:05:45 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 3This portion of our Emerging Trends Conference Roundtable looks at how therapy might evolve over time. Aleksander Krag starts by discussing a presentation on what we can learn from bariatric surgery in terms of fibrosis reduction and why pharmacotherapies work (or not). He envisions a day where we have multiple treatment options and understanding how each works for specific types of patients, leading to robust, cost-effective, patient-specific treatment algorithms.  Alex Lalos describes how presentations on FGF-21s in advanced fibrosis and cirrhosis have whetted his appetite and Jenn Jones asks questions regarding ALD patient trial selection and assignment and clinical endpoints for cirrhosis trials. 00:16:55 - Newsmakers: FibroSIGHT Brings Clinical Trial Analytics to Clinical Practice Use of BiopsyYukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology to determine specific CRN fibrosis level for patients with inconclusive NIT results.  Yukti states that demand for this technique could equal 163,000 cases this year and rising to one million by 2028. She provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit, but expresses concern that any option requiring more biopsies will reduce the number of patients treated.00:41:49 - Patient Advocate and Policy Expert Jeff McIntyre Discusses the Implications of FA/NIH Job Cuts on MASLD Patient CareGlobal Liver Institute Vice President, Liver Programs Jeff McIntyre joins Roger to discuss the April 1 job reductions at the FDA, explore implications for the entire MASLD community, and to ask what patients can and should do. Jeff and Roger note that the job changes will create significant uncertainty and probably reduce the government's ability to respond to future health crises. Jeff notes former FDA Commissioner Rob Califf's comment that the FDA as we know it "is dead," and that we have little idea what the future holds. According to Jeff, patients need to become even more vigilant self-advocates and also seek the guidance and support they need from patient advocacies. Finally, the conversation turns to discuss FibroSIGHT. Jeff describes FibroSIGHT as "exactly where we should be and should not be at the same time," a technology that takes a large step forward in understanding and patient support, but one that ties us to biopsy as a standard for clinical care. Jeff and Roger agree this issue will play out over the coming years. 01:09:18 - Business ReportRoger thanks listeners quoting a letter from one of them, and describes the next round of episodes. 

Today's guest is Panos Karelis, Director of Customer Experience and Insights at Intelligencia AI. Intelligencia AI is a life sciences technology company that uses proprietary data, biomedical expertise, and AI-driven algorithms to assess the probability of technical and regulatory success for drug candidates, helping pharmaceutical companies make informed decisions on which drugs to advance or discontinue. Panos joins us on today's show to explore the key challenges and opportunities in AI adoption for drug development. He discusses the “black box” problem in AI and the importance of transparency and explainability in building trust. Panos also highlights the role of high-quality, harmonized data in generating accurate AI-driven insights and the mindset shift required for organizations to integrate AI-assisted decision-making successfully. Additionally, he explains how AI can optimize clinical trial design, enhance portfolio management, and improve business development and licensing decisions. This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Liz is joined by Dr. Varun Malhotra on the podcast this month to discuss clinical competency exams for clinical support reps. As both a practicing physician and an industry leader, he shares invaluable perspective on both how a rep should act in the OR and how companies should prepare reps to do so. In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Related Resources:Dr. Varun Malhotra is an ophthalmologist with specialized training in glaucoma who has successfully bridged the worlds of clinical practice and biotechnology innovation.Dr. Malhotra completed his undergraduate education at Dartmouth College before earning his medical degree from New York University School of Medicine. He continued at NYU for his ophthalmology residency, gaining comprehensive training in diagnosing and treating various eye conditions. His education was further enhanced with a specialized fellowship in glaucoma at the prestigious Illinois Eye and Ear Infirmary, where he developed expertise in managing this complex eye disease.With additional credentials including an MBA from the University of Chicago Booth School of Business, Dr. Malhotra cultivated a multifaceted career spanning both academic and private practice settings before making a strategic transition to the biotechnology sector with a role at Genentech, where he was the clinical lead for the Port Delivery System Diabetic Macular Edema program. He also served as the global surgical lead for the entire Port Delivery System, where he oversaw the expansion and surgical training for all internal and external stakeholders of ophthalmic clinical trials from the United States to encompass countries in Europe, South America, and Asia.Dr. Malhotra is currently the Vice President of Clinical Development for Ollin Bioscience, an ophthalmic biotech company. He still practices ophthalmology and trains resident physicians in clinical and surgical skills on a weekly basis. Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe!Connect with us on LinkedIn:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Varun MalhotraCumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠About Cumby Consulting:   Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality."

Finding the right amount of therapy materials is a struggle for many clinicians. It's hard to find the balance between having enough options, without having so many choices it feels overwhelming.Now that we have access to digital resources, we also have to think about how to use technology responsibly and effectively. That's why I invited Dr. Karen Rose to episode 204 of the De Facto Leaders podcast to discuss how digital platforms can minimize cognitive fatigue and improve communication on multidisciplinary teams. Dr. Karen Rose has over two decades of experience as a pediatric speech and language pathologist, fueling her passion for improving healthcare. As the former Vice President of Research and Clinical Development at Cognishine, she provided clinical and academic guidance and contributed to numerous research projects. She is now engaged in postdoctoral research and continues to work with Cognishine as an external advisor. Her work has been published in numerous internationally renowned journals.In this conversation, we discuss:✅How different clinical disciplines can collaborate with each other, as well as IT professionals to create engaging therapy resources.✅Using technology to enhance (but not replace) interactive in-person experiences.✅Thinking of digital platforms and therapy materials as a communication tool for team collaboration and parent coaching. ✅Leveraging online materials to provide scaffolding for therapists so they don't have to start from scratch; while still allowing room for engagement and creativity. Learn more about Cognishine here: https://www.cognishine.com/Follow Cognishine on LinkedIn here. https://www.linkedin.com/company/cognishine-therapy-and-education-ltd/Explore some of Congishine's Educational Resources and Free Activities here: https://app.cognishine.com/en-us/free-activitiesConnect with Dr. Karen on LinkedIn directly here: https://www.linkedin.com/in/karen-rose-228757327/ In this episode, I mention the School of Clinical Leadership, my program that helps related service providers develop a strategic plan for putting executive functioning support in place in collaboration with their school teams. You can learn more about that program here: https://drkarendudekbrannan.com/clinicalleadership We're thrilled to be sponsored by IXL. IXL's comprehensive teaching and learning platform for math, language arts, science, and social studies is accelerating achievement in 95 of the top 100 U.S. school districts. Loved by teachers and backed by independent research from Johns Hopkins University, IXL can help you do the following and more:Simplify and streamline technologySave teachers' timeReliably meet Tier 1 standardsImprove student performance on state assessments

What separates top-performing medical sales reps from the rest?  It's not just talent; it's elite training. Amy Harrington, VP of Clinical Training, reveals how the right approach to learning can make or break your success in this industry. Inside this episode: How Amy went from surgical tech to nurse to top-tier medical sales leader Why sales training isn't optional—it's the secret weapon for dominating the field The overlooked power of personalized learning in high-stakes industries How startups shaped her ability to adapt, innovate, and build winning teams Whether you aim to break in, level up, or reinvent your career, this episode delivers the insider playbook for thriving in medical sales. Meet the guest:  Amy Harrington is the Vice President of Clinical Training and Practice Development at R2 Technologies, Inc., where she leads the company's clinical education and advancement strategies. With over a decade of experience in the aesthetic and medical technology industries, Amy is known for designing innovative training programs that equip sales teams to sell confidently through science and knowledge. Since joining R2 in 2021, Amy has been a driving force behind the company'scompany's growth and innovation. Her strategic leadership—first as Director of Clinical Development & Education, then as Senior Director of Clinical Development, and now as VP of Practice Development—has been instrumental in establishing the R2 brand within clinical practices. Her contributions reflect a deep commitment to advancing the field of aesthetics through education and collaboration. Before R2, Amy held impactful leadership roles at Syneos Health, Obagi, and Solta Medical, where she developed and implemented transformative clinical and sales training programs. Beginning her career as a Registered Nurse in the operating room, she gained invaluable hands-on experience that continues to inform her practical and patient-centered approach to clinical education. Amy's academic background includes a dual bachelor's Degree in nursing and biology from the University of Maine, as well as an associate's Degree in criminalistics. She further enhanced her expertise in curriculum development with an instructional design certification from the Association of Talent Development. Outside of her professional endeavors, Amy is a wellness enthusiast who enjoys yoga, rowing, and exploring Maine's landscapes. A proud dog mom, she embraces an active outdoor lifestyle while balancing her passion for transforming clinical education with her love for the outdoors.  Connect with her:  LinkedIn Instagram

In this episode of Medical Affairs Unscripted, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, engages in an enlightening discussion with Smitha Sivaraman, PhD, MBA, Vice President of Medical Affairs at Verastem Oncology. Their discussion highlights the growing trend of integrating Medical Affairs into the Clinical Development process, and how this integration can streamline development when executed properly. Dr. Sivaraman shares her insights on the expectations for Medical Affairs teams working alongside clinical development, the ideal timing for their involvement, and how their role should progress over time. They also discuss the necessary skills and qualities that Medical Affairs team members need to collaborate effectively with Clinical Development, as well as the additional training that could be advantageous. Lastly, they cover what defines success in this emerging trend.

A few weeks ago, Sernova they announced their cell pouch system of islet cell transplants has seen seven people achieve insulin independence and has kept one person off of insulin injections for four years. What does that really mean going forward? I'm talking to their new CEO Jonathan Rigby and to Frank Shannon, Senior Vice President, Clinical Development and Regulatory Affairs More about Sernova here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

In this episode, Dr. Alexandria Wise celebrates 15 years of innovation at CNS Summit 2024 by sitting down with Kevin Craig, Senior Vice President of Clinical Development at atai Life Sciences. Recorded from the floor of the conference, Kevin shares his journey from research and medicine to leading drug development in mental health, with a focus on the company's pioneering work in psychedelics.This episode delves into the complexities of drug development in the psychedelic space, the importance of global accessibility, and the profound impact of patient involvement in clinical trial design. Kevin also shares his perspective on the future of the life sciences industry, emphasizing the role of big data, biomarkers, and efficient trial models in advancing mental health care.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Sonal Gupta, MD, PhD, SVP and Head of Clinical Development at Affyimmune Therapeutics talks with host Emily Walsh Martin, PhD, to explore the challenges of cell therapy clinical trials and how to move patients quickly and thoughtfully through the steps required to receive therapy in aggressive solid tumor cancers.  But first, "we've moved straight from pumpkin spice season into ASGCT Annual Meeting registration season," as Dr. Walsh Martin says. So hop online and join ASGCT, then register and take advantage of the incredible member discounts on Annual Meeting registration. We'll see you in New Orleans, May 13-17, 2025! AnnualMeeting.ASGCT.org/register Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Part 4 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Dr. Jared Baeten, Senior Vice President of Clinical Development and Virology Therapeutic Area Head at Gilead Sciences, joins me to discuss the incredible advancements in pre-exposure prophylaxis (PrEP) treatments in honor of World AIDS Day. What if a twice yearly shot could replace a daily pill? Listen now to learn more!

Part 3 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Part 2 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD-PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Part 1 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD-PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Dr. Ahmed is the Director of Research and Operations for METAVOMetavo is a first of its kind high concentration of AvoB, the natural compound found in avocados which restores and promotes true metabolic health.With a doctoral degree in Food Science from the University of Guelph, Dr. Ahmed has emerged as a trailblazer in the field of metabolic health and nutritional biochemistry. He hit the scene with a groundbreaking doctoral thesis titled "Clinical Development of Avocado-Derived Lipids as Modulators of Fatty Acid Oxidation for the Treatment and Management of Metabolic Disorders." This seminal work laid the foundation for the development of innovative solutions that form the core of Metavo's product offerings. Currently serving as the Director of Research at SP Nutraceuticals, Dr. Ahmed has been pivotal in the product development and successful launch of Metavo, the flagship natural health product that leverages the benefits of avocado for metabolic well-being. TNoteworthy is Dr. Ahmed's role as the study director for the first-in-human clinical trial of Metavo and his current role in conducting further clinical research on Metavo.Join Ken and Eric on the GCP as they learn from Dr. Ahmed all bout the natural ways to boost metabolic health with METAVO!https://www.metavo.com/

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Editor-in-Chief Alan Weil interviews Jennifer Kao of the University of California Los Angeles on her recent paper that explores the impact of the Food and Drug Administration's breakthrough therapy designation program on the reduction of late-stage drug development time.Order the July 2024 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone. Subscribe to UnitedHealthcare's Community & State newsletter.

Learn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs. =============== One of the first interviews devoted to the pharma industry featured Dr. Laura McKain in September 2021. Dr. McKain received her medical degree from Georgetown University in Washington, DC, and completed her training in obstetrics and gynecology at Virginia Commonwealth University in Richmond, Virginia. She was in private practice for over twelve years where her clinical interests included wellwomen care, contraception, HPV, menopause management, as well as general and high-risk obstetrics. In 2008 she transitioned her career to the pharmaceutical industry where she was involved in clinical development projects encompassing a broad range of therapeutic areas. She was involved in bringing two new therapeutics to market. She recently retired from full-time work and is now focused on helping other physicians find new nonclinical careers. She is a career coach and resumé expert at mckainconsulting.com. Laura is the founder of the Physician Nonclinical Career Hunters Facebook Group. With almost 30,000 members, it is the premier group where physicians connect with other physicians, share advice, find job openings, and obtain valuable advice and mentorship about nonclinical careers. In today's interview, Laura and I will be talking about strategies for finding a pharma job in the area of Clinical Development. You will find all of the links mentioned in the episode at https://nonclinicalphysicians.com/land-a-pharma-clinical-development-job/